Jerini Signs Collaboration Agreement with Baxter to Develop Peptide for Use in Therapeutic Protein Purification
News Jan 15, 2008
Under the terms of the agreement, Jerini will use its Peptides-to-Drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers key advantages over conventional antibody-assisted protein purification.
"We are very pleased to announce our fourth collaboration agreement with Baxter. Jerini's proprietary P2D technology platform offers a unique and highly effective approach in the development of novel peptidomimetics or small molecules with applications in protein purification as well as drug development," said Jens Schneider-Mergener, Chief Executive Officer at Jerini.
Under the terms of the agreement, Jerini will receive an upfront payment and full time equivalents (FTE) funding along with potential milestone payments for the achievement of discovery, preclinical, and clinical goals and royalties on eventual product sales.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE